What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 1
- “A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations.”In the company’s words, NCT02381886 on ClinicalTrials.gov
Other drugs for Advanced Malignancies That Harbor IDHR132 Mutations
- Pivekimab SunirineAbbVie · Phase 2/3
- QTX-2101Quetzal Therapeutics · Phase 3
- ZiftomenibKura Oncology, Inc. · Phase 3
- QuizartinibDaiichi Sankyo · Phase 3
- MocravimodPriothera SAS · Phase 3
- ATOSDK Therapeutics, Inc. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | 7 Dec 2016 | A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026